| General Information | |
|---|---|
| ZINC ID | ZINC000036294936 |
| Molecular Weight (Da) | 375 |
| SMILES | Cc1ccc2c(=O)c(C(=O)NC3CCCCC3)cn(Cc3ccccc3)c2n1 |
| Molecular Formula | C23N3O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 108.723 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| LogP | 4.358 |
| Activity (Ki) in nM | 10 |
| Polar Surface Area (PSA) | 63.99 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 1.04654538 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.35 |
| Ilogp | 3.24 |
| Xlogp3 | 3.55 |
| Wlogp | 3.82 |
| Mlogp | 2.84 |
| Silicos-it log p | 4.18 |
| Consensus log p | 3.52 |
| Esol log s | -4.5 |
| Esol solubility (mg/ml) | 0.0119 |
| Esol solubility (mol/l) | 0.0000318 |
| Esol class | Moderately |
| Ali log s | -4.58 |
| Ali solubility (mg/ml) | 0.0099 |
| Ali solubility (mol/l) | 0.0000264 |
| Ali class | Moderately |
| Silicos-it logsw | -7.1 |
| Silicos-it solubility (mg/ml) | 0.00003 |
| Silicos-it solubility (mol/l) | 7.98E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.07 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.84 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.963 |
| Logd | 3.41 |
| Logp | 4.083 |
| F (20%) | 0.076 |
| F (30%) | 0.972 |
| Mdck | 2.01E-05 |
| Ppb | 0.9403 |
| Vdss | 2.296 |
| Fu | 0.05 |
| Cyp1a2-inh | 0.455 |
| Cyp1a2-sub | 0.169 |
| Cyp2c19-inh | 0.805 |
| Cyp2c19-sub | 0.1 |
| Cl | 2.92 |
| T12 | 0.076 |
| H-ht | 0.573 |
| Dili | 0.648 |
| Roa | 0.282 |
| Fdamdd | 0.729 |
| Skinsen | 0.396 |
| Ec | 0.003 |
| Ei | 0.016 |
| Respiratory | 0.617 |
| Bcf | 0.818 |
| Igc50 | 4.043 |
| Lc50 | 4.52 |
| Lc50dm | 5.061 |
| Nr-ar | 0.137 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.59 |
| Nr-aromatase | 0.762 |
| Nr-er | 0.281 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.377 |
| Sr-are | 0.426 |
| Sr-atad5 | 0.146 |
| Sr-hse | 0.469 |
| Sr-mmp | 0.358 |
| Sr-p53 | 0.38 |
| Vol | 398.981 |
| Dense | 0.94 |
| Flex | 0.2 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 0.754 |
| Synth | 2.15 |
| Fsp3 | 0.348 |
| Mce-18 | 50.129 |
| Natural product-likeness | -1.235 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |